{
    "clinical_study": {
        "@rank": "99353", 
        "brief_summary": {
            "textblock": "The objective of this double-blind placebo-controlled study is to evaluate the effect of\n      Isoprinosine in a group of homogenous male volunteers who present with immunologic defects\n      relative to:\n\n        -  Comparison of total helper and suppressor T-cell number between the groups.\n\n        -  Comparison of the phytohemagglutinins (PHA) and concanavalin A lymphoproliferative\n           response and natural killer (NK) cell activity between the groups.\n\n        -  Determination of the clinical course of the volunteers after discontinuance of\n           Isoprinosine."
        }, 
        "brief_title": "A Double-Blind Placebo Controlled Study To Determine the Optimal Immunopharmacological Dose Level of Isoprinosine in Immunodepressed Volunteers", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  Opportunistic infections or Kaposi's sarcoma.\n\n          -  Critical illness.\n\n          -  History of gout, urolithiasis, nephrolithiasis, renal dysfunction, and severe gastric\n             ulcer.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Steroids.\n\n          -  Cytotoxic immunosuppressive agents.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Radiotherapy.\n\n        The following are excluded:\n\n          -  Opportunistic infections or Kaposi's sarcoma.\n\n          -  Critically ill patients.\n\n          -  Patients receiving steroids, cytotoxic immunosuppressive agents, and/or radiotherapy.\n\n          -  Patients who have received any other immunotherapy.\n\n          -  Patients with a history of gout, urolithiasis, nephrolithiasis, renal dysfunction,\n             and severe gastric ulcer.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Any other immunotherapy.\n\n        Patients who fall into the group which is at risk of developing cutaneous sarcoma and/or\n        opportunistic diseases but at present have no signs or symptoms of these diseases."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002059", 
            "org_study_id": "008E", 
            "secondary_id": "ISO-133-USA"
        }, 
        "intervention": {
            "intervention_name": "Inosine pranobex", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Inosine Pranobex"
        }, 
        "keyword": [
            "T-Lymphocytes, Suppressor-Effector", 
            "Neoplasms", 
            "Inosine Pranobex", 
            "Killer Cells", 
            "T-Lymphocytes, Helper-Inducer", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Laguna Hills", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92656"
                }, 
                "name": "Newport Pharmaceuticals International Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Double-Blind Placebo Controlled Study To Determine the Optimal Immunopharmacological Dose Level of Isoprinosine in Immunodepressed Volunteers", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002059"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Newport Pharmaceuticals International", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 1989"
    }, 
    "geocoordinates": {
        "Newport Pharmaceuticals International Inc": "33.599 -117.699"
    }
}